Advances in reducing the burden of vascular disease in type 2 diabetes

John Chalmers, Rohina Joshi, Anushka Patel

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


1. The epidemic of diabetes is accelerating and the World Health Organization estimates that the number of people affected worldwide will grow from 171 million in 2000 to 366 million by 2030. 2. The main causes of death and disability in individuals with type 2 diabetes are macrovascular and microvascular disease, and blood pressure is one of the main determinants of vascular complications in this population. 3. While randomized trials have demonstrated that blood pressure lowering reduces vascular complications in subjects with type 2 diabetes and hypertension, ADVANCE was designed to determine whether the addition of a fixed combination of perindopril and indapamide, on top of comprehensive and effective cardiovascular treatments and glucose control therapy, would produce further benefits, irrespective of the initial blood pressure. 4. The blood pressure lowering arm of ADVANCE has demonstrated that the simple addition of the fixed combination of perindopril and indapamide compared to matching placebo, significantly reduces combined macrovascular and microvascular complications by 9%, all-cause mortality by 14% and cardiovascular death by 18%. It also reduces total coronary events by 14% and all renal events and microalbuminuria by 21%. 5. Similar benefits were observed in participant sub-groups characterized by age, sex, baseline blood pressure, previous vascular diseases and concomitant cardiovascular therapy including blood pressure lowering therapy. 6. Successful implementation of this treatment, with a single combination tablet of perindopril and indapamide, should be practical and affordable in most clinical settings worldwide and has the capacity to save countless lives and to reduce the burden of coronary disease and renal disease burden among millions of people with type 2 diabetes.

Original languageEnglish
Pages (from-to)434-437
Number of pages4
JournalClinical and Experimental Pharmacology and Physiology
Issue number4
Publication statusPublished - Apr 2008
Externally publishedYes


  • All-cause mortality
  • Blood pressure lowering
  • Cardiovascular deaths
  • Microalbuminuria
  • Perindopril-indapamide fixed combination
  • Total coronary events
  • Total macrovascular and microvascular disease
  • Total renal events
  • Type 2 diabetes


Dive into the research topics of 'Advances in reducing the burden of vascular disease in type 2 diabetes'. Together they form a unique fingerprint.

Cite this